ArticleAntibiotics (Basel, Switzerland)2021
Conservative Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Retrospective Cohort Study.
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06917846 (Is Medical Therapy Alone Efficient for the Management of Medication-Related Osteonecrosis of the Jaw Bones), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Is Medical Therapy Alone Efficient for the Management of Medication-Related Osteonecrosis of the Jaw Bones (MRONJ) in All Stages?: A Comparative Study
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Reduction of MRONJ risk after exodontia by virtue of ozone infiltration: A randomized clinical trial.Oral diseases · 2024Trial
- Medication-related osteonecrosis of the jaw in cancer and osteoporosis patients: a retrospective seven-year single-center Norwegian cohort study of clinical profiles and documented soft tissue healing.Acta odontologica Scandinavica · 2026Article
- Review
- Pentoxifylline and Tocopherol for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Retrospective Clinical Audit.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical characteristics of osteonecrosis of the jaw related to denosumab: a 5-year retrospective cohort study.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2026Article
- Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols.Frontiers in medicine · 2026Review
- Anti-resorptive therapy for osteoporosis and oral status of geriatric inpatients: A retrospective hospital-based study.Journal of clinical and experimental dentistry · 2025Review
- Clinical efficacy analysis of mucoperiosteal flap combined with perforation technique for tooth extraction in medication-related osteonecrosis of the jaw risk population: a retrospective study.BMC oral health · 2025Article
- Comprehensive Review of Prevention and Management Strategies for Medication-related Osteonecrosis of the Jaw (MRONJ).Oral health & preventive dentistry · 2025Review
- Is medical therapy alone efficient for the management of Medication-related osteonecrosis of the jaw bones (MRONJ) in all stages?: a comparative single-center case-control study.BMC oral health · 2025Observational
- Comparison of non-medication-related osteonecrosis and medication-related osteonecrosis of the jaw: a pilot study.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2025Article
- Bisphosphonate-Related Osteonecrosis of the Jaw: A 10-Year Analysis of Risk Factors and Clinical Outcomes.Journal of clinical medicine · 2025Article
- How does medication-related osteonecrosis of the jaw (MRONJ) influence the health-related quality of life after surgery?BMC oral health · 2025Article
- Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol.Journal of clinical medicine · 2025Article
- Combination of Different Laser Wavelengths as a Treatment Strategy for Maxillary Osteonecrosis: A Case Report.Journal of lasers in medical sciences · 2025Article
- Management of Medication-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients With Pentoxifylline and Tocopherol: Case Reports.Case reports in dentistry · 2025Article
- Bridging the gap - Establishing a dental-oncology service in a cancer centre.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- How we manage medication-related osteonecrosis of the jaw.European journal of medical research · 2024Review
- Platelet-Rich Fibrin Treatment Evaluation in Patients with Medication-Related Osteonecrosis of the Jaw and Osteoradionecrosis.Journal of clinical medicine · 2024Article
- Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication-related osteonecrosis of the jaw (MRONJ) is a severe side effect of bisphosphonates and anti-resorptive drugs prescribed for treatment of severe osteoporosis, Paget's disease, and bone malignancies. The aim of this study was to evaluate the clinical outcome of a combined pharmacological and surgical management strategy on patients affected by MRONJ. MATERIALS AND
methodsMedical records of patients with MRONJ were retrospectively examined to collect clinical history data. Conservative management included an initial pharmacological phase with antibiotics and antiseptic agents, followed by surgical intervention to remove bone sequestrum. Primary outcomes were healing from MRONJ at short term (1 month after surgery) and at longer term (3 months after surgery). Secondary outcome was assessment of recurrences at longer-term follow-up.
resultsThirty-five patients were included in the study with mean follow-up of 23.86 ± 18.14 months. Seven cases showed spontaneous exfoliation of necrotic bone during pharmacological therapy, which in one case did not require any further intervention. At 1-month posttreatment, 31 out of 35 (88.5%) patients showed complete healing. The 25 patients who were followed for at least 3 months revealed a healing rate of 92% (23/25). Recurrences occurred in 7 patients out 23 who showed the long-term healing, after a mean period of 7.29 ± 3.45 months. The prognostic score (University of Connecticut Osteonecrosis Numerical Scale-UCONNS) was significantly higher (
conclusionsA MRONJ treatment approach based on a combined pharmacological and surgical treatment strategy showed a high rate of healing and few recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.